Pre-Clinical Trials
Our core technology is the development of a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
Oklahoma’s 1980s Oil Problems Leads to Career in Biotechnology for Local Lawyer
April 26, 2016 – Excerpt from NewsOk: “Through an association with William Hagstrom of Alpha Bio Partners, Branch became acquainted with OU professor Anne Pereira,…
Read MoreHeloise Anne Pereira named 2016 National Academy of Inventors Fellow
December 16, 2015 – Excerpt from OCRID: University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of…
Read MoreBiolytx funds raised
November 7, 2015 – Excerpt from NewsOK: A $500,000 investment from the i2E Inc.-managed Oklahoma Seed Capital Fund recently led a $1.1 million financing round…
Read MoreBiolytx Pharmaceuticals Targets Drug-Resistant Bacteria
March 25 , 2015 – Excerpt from: Oklahoma JustGoodNews.Biz OKLAHOMA CITY — In 2004, i2E launched a “Meet the Scientist” speaker series in which Oklahoma researchers…
Read More